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A b s t r a c t
Background: Transcatheter aortic valve implantation (TAVI) has evolved as an effective treatment in patients with symptomatic 
severe aortic stenosis (AS) and increased operative risk. Data on the influence of previous sternotomy on the risk of TAVI are 
limited. 
Aim: We sought to investigate the effect of previous cardiac surgery with sternotomy on clinical outcomes and quality of life 
(QoL) after TAVI.
Methods: The study included 148 consecutive patients with symptomatic severe AS, who underwent TAVI. Baseline charac­
teristics, procedural and long-term clinical outcomes, and QoL assessment with the EQ-5D-3L questionnaire were compared 
between patients with and without previous sternotomy.
Results: Patients with previous sternotomy (23.0% of the population) were younger and more often male, had higher rate of 
previous myocardial infarction (MI; 26 [22.8%] vs. 22 [64.7%], p = 0.001), and lower median left ventricular ejection frac­
tion (60.0% [50.0–65.0] vs. 50.0% [42.0–60.0], p = 0.004). Periprocedural risk measured with the Logistic Euroscore and 
the Society of Thoracic Surgeons scale was comparable in both groups. There were no differences in 30-day and 12-month 
all-cause mortality between the groups with and without sternotomy (10 [8.8%] vs. 2 [5.9%], p = 0.7; odds ratio [OR] adjusted 
for age/sex/previous MI, 0.56, 95% confidence interval [CI] 0.10–3.29; for 12-month mortality adjusted OR 0.19, 95% CI 
0.04–0.99). At the longest available follow-up, mortality was higher in patients without sternotomy (30 [26.3%] vs. 3 [8.8%], 
p = 0.03; adjusted OR 0.10, 95% CI 0.02–0.42). Similar rates of other complications after TAVI were noted. No differences 
in the EQ-5D-3L questionnaire at baseline and 12-month follow-up were confirmed. 
Conclusions: TAVI seems to be a safe and effective technique for the treatment of severe AS in patients with previous cardiac 
surgery. 
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has been demon­
strated as an effective treatment in patients with symptomatic 
severe aortic stenosis (AS) and increased operative risk [1–3]. 
An improvement in clinical outcomes and quality of life (QoL) 
after TAVI in long-term follow-up was confirmed by several 
studies [4–8]. Patients with previous cardiac surgery are con­
sidered to be at increased perioperative risk for redo cardiac 
operations [9, 10]. Previous cardiac surgery imposes additional 
risks on patients undergoing median sternotomy [11–13]. 
Furthermore, patients with a history of coronary artery bypass 
grafting (CABG) may face an additional risk of damage to the 
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graft, which is associated with worse periprocedural outcomes 
[11–13]. Nowadays, these patients constitute a considerable 
portion of those with severe AS referred for TAVI due to the 
minimally invasive nature of this approach. However, out­
comes of patients with previous sternotomy undergoing TAVI 
are still under investigation. Thus, we sought to investigate the 
impact of previous cardiac surgery with sternotomy on clinical 
outcomes and QoL after TAVI.
METHODS
A complete description was reported previously [14]. We en­
rolled 148 consecutive patients who underwent TAVI. All the 
patients had symptomatic severe AS and high periprocedural 
risk or contraindications for surgical aortic valve replacement. 
The eligibility for TAVI was based on the consensus of the mul- 
tidisciplinary Heart Team. Baseline characteristics and proce­
dural data were collected prospectively. TAVI procedures were 
performed using Edwards Sapien, Edwards Sapien XT, Edwards 
Sapien 3 (Edwards Lifesciences, Irvine, CA, USA), Medtronic 
CoreValve/Evolut R (Medtronic, Inc., Minneapolis, MN, USA), 
JenaValve (JenaValve Technology, Munich, Germany), Lotus 
(Boston Scientific), and New Valve Technology transcatheter 
heart valves. The decision about the type and size of the valve 
as well as the access route was at the discretion of the Heart 
Team and treating physicians. Procedures were performed 
under general anaesthesia or local anaesthesia with sedation. 
Clinical endpoints of the study included all-cause mortality 
at 30 days and every six months up to maximal available fol­
low-up and complications rate up to 12 months. QoL was as­
sessed with the validated Polish version of the EQ-5D-3L ques­
tionnaire at baseline and 12 months after TAVI. The visual ana­
logue scale (VAS) score, which is a part of the EQ-5D-3L, was 
also assessed. Outcome endpoints were in accordance with 
Valve Academic Research Consortium definitions (VARC-2) 
[15]. For this analysis, patients were divided into two groups 
according to the presence of cardiac surgery with sternotomy. 
Written informed consent was collected from each patient 
included in the study. The study was approved by the insti­
tutional ethical board and was conducted according to the 
ethical guidelines of the 1975 Declaration of Helsinki with 
later amendments.
Statistical analysis
Results are presented as number of patients (percentage) or 
median (interquartile range [IQR]), where applicable. Differ­
ences between groups were tested using the c2 test and Fisher’s 
exact test for dichotomous variables and the Mann-Whitney 
U-test for continuous variables. Changes in EQ-5D-3L ques­
tionnaire between baseline and follow-up evaluations were 
analysed using McNemar’s test. The relationship between 
baseline and follow-up responses in the VAS score were 
analysed with a Wilcoxon signed-rank test. Comparisons of 
baseline and 12-month outcomes were calculated excluding 
unpaired results. The difference in mortality between patients 
with and without previous sternotomy during follow-up was 
assessed with Kaplan-Meier method. In addition, differences 
in outcomes were presented as odds ratios (ORs) adjusted 
for age/sex/previous myocardial infarction (MI) with 95% 
confidence intervals (CIs). Multivariable Cox regression model 
was constructed to identify significant predictors of 12-month 
mortality. All baseline characteristics and procedural data were 
considered and forward selection with a probability value for 
covariates to enter the model of 0.05 was used. Results were 
presented as hazard ratios (HRs) with 95% CI. All tests were 
two-tailed, and a p-value of < 0.05 was considered statisti­
cally significant. All statistical analyses were performed using 
SPSS 15.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS 
Of the 148 consecutive patients undergoing TAVI, previ­
ous cardiac surgery with sternotomy was confirmed in 
34 (23.0%), and previous CABG was the reason for ster­
notomy in 28 (82.4%) of these 34 patients with a history 
of cardiac surgery. Patients with previous sternotomy were 
younger and were more often male, with a higher rate of 
previous MI (26 [22.8%] vs. 22 [64.7%]; p = 0.001; Table 1). 
Similar rates of other comorbidities were reported in both 
groups. Furthermore, no difference in periprocedural risk 
measured with Logistic Euroscore and the Society of Thoracic 
Surgeons (STS) was noted. Procedural details are presented 
in Table 2. A comparable length of hospital stay was ob­
served in patients with and without a history of sternotomy 
(10.0 [8.5–12.0] vs. 10.0 [8.0–13.5] days; p = 0.80). No dif­
ferences between groups in all components of the EQ-5D-3L 
questionnaire were confirmed at baseline and 12 months after 
TAVI (Fig. 1). The median VAS at baseline (40.0 [30.0–50.0] 
vs. 41.0 [40.0–70.0]; p = 0.20) and 12 months after TAVI 
(70.0 [60.0–80.0] vs. 70.0 [62.5–80.0]; p = 0.60) was 
comparable between groups. Similarly, no difference in 
VAS change during follow-up was noted between groups 
(30.0 [15.0–40.0] vs. 17.5 [10.0–30.0]; p = 0.07). Lower 
median of left ventricular ejection fraction before (60.0% 
[50.0–65.0] vs. 50.0% [42.0–60.0], p = 0.004) and after 
TAVI procedure (49.0% [45.0–55.0] vs. 45.0% [35.0–50.0], 
p = 0.05) was confirmed in patients with previous sternotomy 
(Table 3). Median follow-up of all patients was 13.3 (6.0–31.1) 
months. There were no differences in 30-day and 12-month 
all-cause mortality between groups (sternotomy [–] vs. ster­
notomy [+]: 10 [8.8%] vs. 2 [5.9%], p = 0.70; 20 [17.5%] 
vs. 2 [5.9%]; p = 0.10, respectively). Also, no influence of 
previous sternotomy on the risk of death was confirmed after 
adjustment for age/sex/previous MI (for 30-day mortality ad­
justed OR 0.56, 95% CI 0.10–3.29; for 12-month mortality 
adjusted OR 0.19, 95% CI 0.04–0.99). However, at the longest 
available follow-up mortality was higher in patients without 
previous sternotomy (30 [26.3%] vs. 3 [8.8%]; p = 0.03, 
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adjusted OR 0.10, 95% CI 0.02–0.42; Fig. 2). Interestingly, 
the difference in mortality was confirmed only for patients 
treated with non-femoral access (10 [45.5%] vs. 0 [0.0%]; 
p = 0.030) with no impact on mortality in patients from the 
femoral access group (20 [21.7%] vs. 3 [12.0%]; p = 0.40). 
Rates of in-hospital grade 3 acute kidney injury (sternotomy [–] 
vs. sternotomy [+]: 7 [6.1%] vs. 1 [2.9%], p = 0.70; adjusted 
OR 0.63, 95% CI 0.06–6.74), bleeding complications (sternot­
omy [–] vs. sternotomy [+]: 41 [36.0%] vs. 8 [23.5%]; p = 0.20; 
adjusted OR 0.65, 95% CI 0.24–1.77), and blood transfusions 
(sternotomy [–] vs. sternotomy [+]: 35 [30.7%] vs. 9 [26.5%], 
p = 0.60; adjusted OR 1.06, 95% CI 0.39–2.90) were compa­
rable between groups. Similarly, no differences in stroke/tran­
sient ischaemic attack (TIA; sternotomy [–] vs. sternotomy [+]: 
9 [5.3%] vs. 4 [11.8%], p = 0.20; adjusted OR 1.94, 95% 
CI 0.39–9.59), MI (sternotomy [–] vs. sternotomy [+]: 
3 [2.6%] vs. 1 [2.9%], p = 0.99; adjusted OR 0.08, 95% 
CI 0.01–2.10), need for permanent pacemaker stimulation 
(sternotomy [–] vs. sternotomy [+]: 20 [17.5%] vs. 4 [11.8%], 
p = 0.40; adjusted OR 0.89, 95% CI 0.24–3.33), and 
new-onset atrial fibrillation (sternotomy [–] vs. sternotomy [+]: 
9 [7.9%] vs. 1 [2.9%], p = 0.50; adjusted OR 0.17, 95% CI 
0.02–1.69) were reported during 12-month follow-up. Pre­
vious cardiac surgery with sternotomy was not identified as 
an independent predictor of mortality in multivariable Cox 
regression analysis. Incomplete coronary revascularisation (HR 
5.45, 95% CI 2.38–12.52; p = 0.001), estimated glomerular 
filtration rate (HR 0.96 per 1 mL/min/1.73 m2 increase, 95% CI 
0.94–0.98; p = 0.001), and previous stroke/TIA (HR 2.86, 
95% CI 1.17–7.00; p = 0.02) were identified as the only 
independent determinants of death.
DISCUSSION
The results of this study suggest no impact of previous car­
diac surgery with sternotomy on the risk of adverse events in 
patients undergoing TAVI as compared with patients with no 




(–) (n = 114)
Previous sternotomy 
(+) (n = 34)
p
Age [years] 82.0 (77.0–85.0) 83.0 (79.0–85.0) 78.0 (73.0–82.0) 0.001
Age ≥ 80 years 92 (62.2%) 81 (71.1%) 11 (32.4%) 0.001
Men 56 (37.8%) 36 (31.6%) 20 (58.8%) 0.004
Body mass index [kg/m2] 27.2 (25.2–30.6) 27.4 (25.4–30.6) 27.0 (24.3–29.9) 0.3
eGFR [mL/min/1.73 m2] 56.5 (40.0–72.0) 54.0 (40.0–71.0) 62.0 (40.5–75.4) 0.5
NYHA class: 0.4
I 0 (0.0%) 0 (0.0%) 0 (0.0%)
II 41 (27.7%) 29 (25.4%) 12 (35.3%)
III 97 (65.5%) 76 (66.7%) 21 (61.8%)
IV 10 (6.8%) 9 (7.9%) 1 (2.9%)
Arterial hypertension 139 (93.9%) 107 (93.9%) 32 (94.1%) 0.99
Diabetes mellitus 48 (32.4%) 41 (36.0%) 7 (20.6%) 0.1
Atrial fibrillation 52 (35.1%) 44 (38.6%) 8 (23.5%) 0.1
Previous MI 48 (32.4%) 26 (22.8%) 22 (64.7%) 0.001
Previous PCI 43 (29.1%) 35 (30.7%) 8 (23.5%) 0.4
Previous CABG 28 (18.9%) 0 (0.0%) 28 (82.4%) 0.001
Coronary chronic total occlusion 14 (9.5%) 12 (10.5%) 2 (5.9%) 0.5
Incomplete revascularisation 22 (14.9%) 18 (15.8%) 4 (11.8%) 0.6
COPD 19 (12.8%) 16 (14.0%) 3 (8.8%) 0.6
Stroke/TIA 17 (11.5%) 13 (11.4%) 4 (11.8%) 0.99
Pacemaker 17 (11.5%) 15 (13.2%) 2 (5.9%) 0.4
Logistic Euroscore I [%] 14.5 (10.0–22.7) 13.5 (10.0–21.0) 18.8 (10.0–27.0) 0.1
Society of Thoracic Surgeons score [%] 6.2 (4.0–17.3) 6.0 (4.0–17.5) 8.0 (5.0–16.0) 0.7
Data are shown as median and interquartile range (IQR) or number and percentage. CABG — coronary artery bypass graft; COPD — chronic 
obstructive pulmonary disease; eGFR — estimated glomerular filtration rate; MI — myocardial infarction; NYHA — New York Heart Association;  
PCI — percutaneous coronary intervention; TIA — transient ischaemic attack
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(–) (n = 114)
Previous sternotomy 
(+) (n = 34)
p
Access type: 0.5
Transfemoral 117 (79.1%) 92 (80.7%) 25 (73.5%)
Transapical 28 (18.9%) 20 (17.5%) 8 (23.5%)
Transaortic 2 (1.4%) 1 (0.9%) 1 (2.9%)
Subclavian 1 (0.7%) 1 (0.9%) 0 (0.0%)
Device implanted: 0.1
Corevalve/Evolut R 29 (19.6%) 16 (14.0%) 13 (38.2%)
Edwards Sapien 95 (64.2%) 78 (68.4%) 17 (50.0%)
Jena 10 (6.8%) 8 (7.0%) 2 (5.9%)
Lotus 9 (6.1%) 8 (7.0%) 1 (2.9%)
NVT 5 (3.4%) 4 (3.5%) 1 (2.9%)
Prosthesis size: 0.1
23 mm 30 (20.3%) 22 (19.3%) 8 (23.5%)
25 mm 8 (5.4%) 8 (7.0%) 0 (0.0%)
26 mm 56 (37.8%) 45 (39.5%) 11 (32.4%)
27 mm 8 (5.4%) 7 (6.1%) 1 (2.9%)
29 mm 38 (25.7%) 29 (25.4%) 9 (26.5%)
31 mm 8 (5.4%) 3 (2.6%) 5 (14.7%)
Prosthesis size [mm] 26.0 (25.0–29.0) 26.0 (25.0–29.0) 26.0 (26.0–29.0) 0.2
Radiation dose [mGy] 721.0 (632.5–827.5) 715.0 (632.0–823.0) 721.0 (673.0–834.0) 0.9
Contrast medium load [mL] 75.0 (50.0–137.5) 75.0 (50.0–100.0) 75.0 (50.0–150.0) 0.8
Fluoroscopy time [min] 13.0 (12.0–15.0) 13.0 (12.0–15.0) 13.0 (11.0–14.0) 0.5 
Data are shown as median and interquartile range (IQR) or number and percentage. NVT — New Valve Technology
Figure 1. Proportions of patients reporting either “some problems” or “extreme problems” for each category of the EQ-5D-3L at 
baseline and 12 months
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history of chest opening. These results were maintained after 
the adjustment for age, sex, and previous MI. No differences in 
the results of QoL assessment were observed between groups.
Previous sternotomy was not identified as an independent 
predictor of all-cause long-term mortality. Observed higher 
long-term mortality in patients without previous sternotomy 
might be partially related to some differences in age and 
baseline risk profile between groups. These data stay in line 
with results from most recent studies reporting no influence of 
prior cardiac surgery on survival rate after TAVI. A recent large 
meta-analysis has reported no significant difference in 30-day 
and one-year all-cause mortality between patients undergoing 
TAVI with and without a history of previous cardiac surgery 
with sternotomy (risk ratio 0.95, 95% CI 0.82–1.09, p = 0.55; 
risk ratio 0.94, 95% CI 0.86–1.02, p = 0.48, respectively) [16]. 
In addition, results of subgroup analysis including only patients 
with a history of CABG also did not show differences between 
those groups [16]. Interestingly, the rate of major vascular 
complications was marginally lower in patients with previous 
cardiac surgery, but the calculation was not robust because 
the result lost significance in sensitivity analysis [16]. Also, the 
risk of acute MI was significantly higher in patients with prior 
sternotomy, but a higher prevalence of coronary artery disease 
(CAD) and diabetes mellitus in the previous cardiac surgery 
group was the probable reason for this worse outcome [16]. 
However, most of the included studies were non-randomised 
or were post hoc analyses of randomised trials; thus, it may 
have limited the external validity of the analysis. In our study, 
no difference in the rate of all complications was confirmed. 
Several studies reported comparable clinical outcomes be­
tween patients with and without a history of prior cardiac 
surgery with sternotomy [17–21]. However, Ducrocq et al. [22] 
Figure 2. Kaplan-Meier curves for survival after transcatheter 
valve implantation stratified by previous sternotomy (without 
previous sternotomy — solid line; with previous sternotomy 
— dotted line)




(–) (n = 114)
Previous sternotomy 
(+) (n = 34)
p
TG max before TAVI [mmHg] 86.0 (69.0–103.0) 86.0 (69.0–104.0) 84.0 (71.0–98.0) 0.5
TG mean before TAVI [mmHg] 50.0 (42.0–63.0) 50.0 (41.0–64.0) 49.5 (42.0–55.7) 0.5
AVA before TAVI [cm2] 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.8 (0.5–0.9) 0.6
LVEF before TAVI [%] 60.0 (50.0–65.0) 60.0 (50.0–65.0) 50.0 (42.0–60.0) 0.004
AR before: 0.5
0 48 (32.4%) 40 (35.1%) 8 (23.5%)
1 75 (50.7%) 56 (49.1%) 19 (55.9%)
2 20 (13.5%) 15 (13.2%) 5 (14.7%)
3 5 (3.4%) 3 (2.6%) 2 (5.9%)
TG max after TAVI [mmHg] 13.0 (10.0–19.0) 13.5 (10.1–19.0) 13.0 (8.0–18.0) 0.2
TG mean after TAVI [mmHg] 7.4 (5.1–10.0) 8.0 (6.0–10.5) 7.0 (5.0–9.0) 0.3
LVEF after TAVI [%] 48.0 (41.0–55.0) 49.0 (45.0–55.0) 45.0 (35.0–50.0) 0.05
AR after TAVI: 0.4
0 84 (56.8%) 64 (56.1%) 20 (58.8%)
1 55 (37.2%) 42 (36.8%) 13 (38.2%)
2 7 (4.7%) 7 (6.1%) 0 (0.0%)
3 2 (1.4%) 1 (0.9%) 1 (2.9%)
Data are shown as median and interquartile range (IQR) or number and percentage. AR — aortic regurgitation; AVA — aortic valve area;  
LVEF — left ventricular ejection fraction; TAVI — transcatheter aortic valve implantation; TG — transvalvular gradient
www.kardiologiapolska.pl
Impact of previous cardiac surgery on TAVI outcomes
843
reported better survival in patients with previous CABG 
undergoing TAVI. Multivariate analysis identified a history of 
CABG as an independent predictor of better two-year survival 
[22]. Conversely, this study also confirmed that transapical ap­
proach (TA) is a predictor of two-year mortality [22]. On the 
other hand, these results may be related to the residual bias 
in an observational nature of this analysis. In our study, we 
did not take into account variables such as the type of valve 
and type of vascular approach, which could affect clinical 
outcomes. Some would argue that TA may be challenging in 
patients with previous sternotomy undergoing TAVI. Few stud­
ies have assessed the outcomes of TA use in TAVI patients with 
prior cardiac operations. The results were similar in patients 
with and without a history of chest opening [17, 23–26]. These 
data suggested that both TA and transfemoral (TF) TAVI are 
reasonable options in patients with severe AS and previous 
cardiac operation. In patients with a history of previous car­
diac surgery with sternotomy, the potential superiority of TAVI 
is linked to the minimally invasive nature of the procedure 
[17]. Small mediastinal dissection (in TA-TAVI and transaortic 
approach) or no incision at all (TF-TAVI and trans-subclavian 
approach) reduce potential risk related to all complications 
associated with chest reopening [17]. Furthermore, no need 
for extracorporeal circulation provides an additional advan­
tage [17]. In contrast, TAVI does not eliminate the fact that 
patients with previous CABG have a history of significant CAD, 
which by itself may result in additive risk [17]. In our study, 
despite a higher rate of previous MI in patients with a history 
of sternotomy, the adverse outcomes were not different in 
comparison with patients with no prior cardiac surgery. The 
vast majority of redo patients had previous CABG operations 
(82.4%), but the incidence of perioperative and long-term MI 
was low. This could be explained by the potential protective 
function of the patent grafts. Furthermore, all patients under­
went diagnostic angiography before they were scheduled for 
TAVI to exclude progression of CAD.
Despite mortality being used to measure the effective­
ness of treatments, QoL should be an additional target [3–5]. 
Thus, QoL improvement is commonly considered as a major 
expectation for elderly patients’ profile after TAVI [3–5, 27, 
28]. Amelioration of QoL after TAVI may be more beneficial 
than observed after surgical treatment of severe AS, even in­
cluding less invasive mini-thoracotomy and mini-sternotomy 
techniques [8]. In our study, no differences between groups 
in all components of the EQ-5D-3L questionnaire were 
confirmed. Similar results in VAS change during follow-up 
were observed in patients with and without history of cardiac 
surgery with chest opening. However, numerically higher 
improvement in patients without previous sternotomy might 
suggest that this result could reach statistical significance with 
a higher number of included patients. 
Most of the limitations are directly related to the non-ran­
domised, observational study design. The decision for suitabil­
ity and eligibility for TAVI was conducted by a multidisciplinary 
local Heart Team according to current guidelines, although 
potential bias in patients and treatment selection could af­
fect the outcomes. Thus, these results should be considered 
as hypothesis-generating rather than causative. There are 
also limitations related to the instrument for QoL evaluation. 
EQ-5D-3L is a generic questionnaire with a low sensitivity. 
Furthermore, no disease-specific QoL tool was used due to 
time-consuming evaluation. CABG was the reason for previ­
ous cardiac surgery in most of the patients. In the remaining 
six patients (17.6% of this group) the indication for previous 
cardiac surgery with sternotomy was not documented. Fur­
thermore, the interval between previous chest opening and 
TAVI was unknown. 
In conclusion, TAVI seems to be a safe and effective 
technique for the treatment of severe AS in patients with 
previous cardiac surgery with sternotomy. Similar complica­
tion rates and QoL outcomes were observed regardless of 
the status of previous cardiac operations. This observation 
might lead the Heart Team to consider TAVI as an attractive 
option in the population of high-risk patients with AS and 
previous sternotomy.
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